Increased Risk of Virologic Rebound in Patients on Antiviral Therapy with a Detectable HIV Load <48 Copies/mL

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Henrich, Timothy J ^a   Wood, Brian R ^a   Kuritzkes, Daniel R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; ETHNICITY; FEMALE; FOLLOW UP; GENDER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; RACE; REBOUND; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; VIREMIA; VIRUS IDENTIFICATION; VIRUS INHIBITION; VIRUS LOAD;

AGE FACTORS; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEX FACTORS; STATISTICS, NONPARAMETRIC; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84869224844     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050065     Document Type: Article

References (16)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents (2011) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services.
2. Lubelchek RJ, Max B, Sandusky CJ, Hota B, Barker DE, (2009) Reliability at the lower limits of HIV-1 RNA quantification in clinical samples: a comparison of RT-PCR versus bDNA assays. PLoS One 4: e6008.
3. Smit E, Bhattacharya S, Osman H, Taylor S, (2009) Increased frequency of HIV-1 viral load blip rate observed after switching from Roche Cobas Amplicor to Cobas Taqman assay. J Acquir Immune Defic Syndr 51: 364-365.
4. Babady NE, Germer JJ, Yao JD, (2010) Results of the Abbott RealTime HIV-1 Assay for Specimens Yielding "Target Not Detected" Results by the Cobas AmpliPrep/Cobas TaqMan HIV-1 Test. J Clin Microbiol 48: 969-971.
5. de Boer MGJ, Wessels E, Claas ECJ, Kroon FP, (2010) Potential Influence of More-Sensitive HIV-1 Load Detection by the new Roche Cobas AmpliPrep/Cobas TaqMan Version 2.0 Assay on Clinical Management of HIV-Positive Pregnant Women. J Clin Microbiol 48: 4301-4302.
6. Pas S, Rossen JWA, Schoener D, Thamke D, Pettersson A, et al. (2010) Performance Evaluation of the New Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Test Version 2.0 for Quantification of Human Immunodeficiency Virus Type 1 RNA. J Clin Microbiol 48: 1195-1200.
7. Pascual-Pareja JF, Martinez-Prats L, Luczkowiak J, Fiorante S, Rubio R, et al. (2010) Detection of HIV-1 at between 20 and 49 Copies per Milliliter by the Cobas TaqMan HIV-1 v2.0 Assay Is Associated with Higher Pretherapy Viral Load and Less Time on Antiretroviral Therapy. J Clin Microbiol 48: 1911-1912.
8. Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, et al. (2012) Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis 54: 724-732.
9. Maggiolo F, Callegaro A, Cologni G, Bernardini C, Velenti D, et al. (2012) Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J Acquir Immune Defic Syndr 60: 473-82.
10. Charpentier C, Landman R, Laouenan C, Joly V, Hamet G, et al. (2012) Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome. J Antimicrob Chemother 67: 2231-5.
11. Gianotti N, Galli L, Racca S, Salpietro S, Cossarini F, et al. (2012) Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. J Antimicrob Chemother 67: 213-217.
12. Pyne MT, Wilson A, Hillyard DR, (2012) Large-scale comparison of Roche Cobas AmpliPrep/Cobas TaqMan and Abbott RealTime HIV assays. J Virol Methods 184: 106-108.
13. Karlsson AC, Younger SR, Martin JN, Grossman Z, Sinclair E, et al. (2004) Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. Aids 18: 981-989.
14. Taiwo B, Gallien S, Aga E, Ribaudo H, Haubrich R, et al. (2011) Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis 204: 515-520.
15. Doyle T, Geretti AM, (2012) Low-level viraemia on HAART: significance and management. Curr Opin Infect Dis 25: 17-25.
16. Willig JH, Nevin CR, Raper JL, Saag MS, Mugavero MJ, et al. (2010) Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test. J Acquir Immune Defic Syndr 54: 442-444.